Lanreotide is a peptide analog of somatostatin that binds to somatostatin receptors (SSTRs) with a higher affinity for the somatostatin subgroup 2 receptors SST2, SST3, and SST5 (IC50s = 0.5-1.8, 43-107, and 5.6-32 nM, respectively) than for the subgroup 1 receptors, SST1 and SST4 (IC50s = 500-2,330 and 66-2,100 nM, respectively).
CAS：127984-74-1
分子式：C54H69N11O10S2.XC2H4O2
分子量：1096.3
纯度：98%
存储：Store at -20°C

Background:

Lanreotide is a peptide analog of somatostatin that binds to somatostatin receptors (SSTRs) with a higher affinity for the somatostatin subgroup 2 receptors SST2, SST3, and SST5 (IC50s = 0.5-1.8, 43-107, and 5.6-32 nM, respectively) than for the subgroup 1 receptors, SST1 and SST4 (IC50s = 500-2,330 and 66-2,100 nM, respectively). Lanreotide (100 nM) inhibits the release of growth hormone from patient-derived pituitary adenoma cells in vitro. It also inhibits tumor growth in human small cell lung cancer (SCLC) mouse xenograft models when administered at a dose of 250 µg, twice daily. Formulations containing lanreotide have been used in the treatment of acromegaly and neuroendocrine tumors.